KR100251895B1 - 포스포디에스테라제 억제제로서의 1,3-디하이드로-2h-이미다조(4,5-b)퀴놀린-2-온 유도체 - Google Patents

포스포디에스테라제 억제제로서의 1,3-디하이드로-2h-이미다조(4,5-b)퀴놀린-2-온 유도체 Download PDF

Info

Publication number
KR100251895B1
KR100251895B1 KR1019940701365A KR19940701365A KR100251895B1 KR 100251895 B1 KR100251895 B1 KR 100251895B1 KR 1019940701365 A KR1019940701365 A KR 1019940701365A KR 19940701365 A KR19940701365 A KR 19940701365A KR 100251895 B1 KR100251895 B1 KR 100251895B1
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
conr
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940701365A
Other languages
English (en)
Korean (ko)
Inventor
쟝 에드가르드 프라이네 에디
헤르만 마르가레타 레이메이커스 알폰스
로베르트 가이 가브리엘 드 샤포이 디디에
Original Assignee
디르크 반테
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디르크 반테, 얀센 파마슈티카 엔.브이. filed Critical 디르크 반테
Application granted granted Critical
Publication of KR100251895B1 publication Critical patent/KR100251895B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1019940701365A 1991-10-30 1992-10-27 포스포디에스테라제 억제제로서의 1,3-디하이드로-2h-이미다조(4,5-b)퀴놀린-2-온 유도체 Expired - Fee Related KR100251895B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78495591A 1991-10-30 1991-10-30
US784.955 1991-10-30
PCT/EP1992/002496 WO1993009118A1 (en) 1991-10-30 1992-10-27 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
KR100251895B1 true KR100251895B1 (ko) 2000-09-01

Family

ID=25134048

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940701365A Expired - Fee Related KR100251895B1 (ko) 1991-10-30 1992-10-27 포스포디에스테라제 억제제로서의 1,3-디하이드로-2h-이미다조(4,5-b)퀴놀린-2-온 유도체

Country Status (24)

Country Link
US (3) US5521187A (enExample)
EP (2) EP0610372B1 (enExample)
JP (1) JP3488922B2 (enExample)
KR (1) KR100251895B1 (enExample)
CN (1) CN1041726C (enExample)
AT (1) ATE131479T1 (enExample)
AU (1) AU660337B2 (enExample)
CA (1) CA2121230C (enExample)
DE (1) DE69206820T2 (enExample)
DK (1) DK0610372T3 (enExample)
ES (1) ES2083773T3 (enExample)
FI (1) FI105548B (enExample)
GR (1) GR3018909T3 (enExample)
HU (1) HU220608B1 (enExample)
IL (1) IL103570A (enExample)
MX (1) MX9206258A (enExample)
NO (1) NO300976B1 (enExample)
NZ (1) NZ244779A (enExample)
PH (1) PH31245A (enExample)
PL (1) PL170749B1 (enExample)
RU (1) RU2127273C1 (enExample)
TW (1) TW249234B (enExample)
WO (1) WO1993009118A1 (enExample)
ZA (1) ZA928373B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5703827A (en) * 1996-02-29 1997-12-30 Monolithic System Technology, Inc. Method and structure for generating a boosted word line voltage and a back bias voltage for a memory array
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) * 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
SK5212003A3 (en) * 2000-10-02 2004-03-02 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP4510384B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
MXPA04009435A (es) * 2002-03-29 2005-01-25 Janssen Pharmaceutica Nv Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico.
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
AR045261A1 (es) 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
EP1797091A2 (en) * 2004-09-14 2007-06-20 Novartis Vaccines and Diagnostics, Inc. Imidazoquinoline compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP1969929A1 (de) 2007-03-12 2008-09-17 Bayer CropScience AG Substituierte Phenylamidine und deren Verwendung als Fungizide
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2651570C2 (ru) 2012-10-02 2018-04-23 Кэлифорниа Инститьют Оф Текнолоджи Силилирование ароматических соединений без переходных металлов
RU2769516C2 (ru) 2012-10-02 2022-04-01 Кэлифорниа Инститьют Оф Текнолоджи Восстановительное расщепление ароматических связей c-s активированными силанами
JP7187149B2 (ja) 2014-08-06 2022-12-12 カリフォルニア インスティチュート オブ テクノロジー 地球に豊富な遷移金属フリ－触媒による芳香族複素環のシリル化
US9556206B2 (en) 2014-09-02 2017-01-31 California Institute Of Technology Base-catalyzed silylation of terminal alkyne C—H bonds
WO2016100606A1 (en) 2014-12-19 2016-06-23 California Institute Of Technology Silylation of aromatic heterocycles by disilanes using potassium alkoxide catalysts
CN110441434A (zh) * 2019-08-29 2019-11-12 重庆华邦胜凯制药有限公司 Gc-ms分离测定对氨基水杨酸中相关杂质的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1602188A (en) * 1977-12-01 1981-11-11 Wellcome Found Hydantoin derivatives
JPS6021941B2 (ja) * 1981-01-28 1985-05-30 株式会社村田製作所 圧電性磁器組成物
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1030196C (zh) * 1989-07-07 1995-11-01 詹森药业有限公司 增强收缩力和舒张力的-二氢咪唑并喹唑啉酮衍生物的制备方法
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.

Also Published As

Publication number Publication date
ES2083773T3 (es) 1996-04-16
IL103570A (en) 1996-03-31
CA2121230C (en) 2003-03-11
HU9401245D0 (en) 1994-08-29
CN1041726C (zh) 1999-01-20
MX9206258A (es) 1993-04-01
WO1993009118A1 (en) 1993-05-13
US5516908A (en) 1996-05-14
AU660337B2 (en) 1995-06-22
DE69206820D1 (de) 1996-01-25
EP0610372A1 (en) 1994-08-17
EP0541153A1 (en) 1993-05-12
FI942010A0 (fi) 1994-04-29
TW249234B (enExample) 1995-06-11
FI942010A7 (fi) 1994-04-29
NO941497L (no) 1994-04-25
HUT66453A (en) 1994-11-28
JPH07500599A (ja) 1995-01-19
GR3018909T3 (en) 1996-05-31
RU2127273C1 (ru) 1999-03-10
ATE131479T1 (de) 1995-12-15
DE69206820T2 (de) 1996-05-15
CA2121230A1 (en) 1993-05-13
NO300976B1 (no) 1997-08-25
NZ244779A (en) 1994-10-26
AU2908392A (en) 1993-06-07
NO941497D0 (enExample) 1994-04-25
JP3488922B2 (ja) 2004-01-19
IL103570A0 (en) 1993-03-15
ZA928373B (en) 1994-04-29
CN1072681A (zh) 1993-06-02
EP0610372B1 (en) 1995-12-13
HU220608B1 (hu) 2002-03-28
PL170749B1 (pl) 1997-01-31
US5521187A (en) 1996-05-28
FI105548B (fi) 2000-09-15
PH31245A (en) 1998-06-18
DK0610372T3 (da) 1996-01-29
US5541325A (en) 1996-07-30

Similar Documents

Publication Publication Date Title
KR100251895B1 (ko) 포스포디에스테라제 억제제로서의 1,3-디하이드로-2h-이미다조(4,5-b)퀴놀린-2-온 유도체
EP0406958B1 (en) Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives
CA1276633C (en) Imidazo-pyridine derivatives
EP1194144B1 (en) Antibacterial compounds
KR100435247B1 (ko) 나프탈렌유도체,그의제조방법,및그의중간체
JPH09507241A (ja) 新規な置換されていてもよいフェニルイミダゾリジン類、それらの製造法及び中間体、それらの薬剤としての用途並びにそれらを含有する製薬組成物
CS187391A3 (en) Heterocyclic derivatives, process for their preparation and their use as medicaments
IT8922768A1 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EA006800B1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
US20020156064A1 (en) Compounds and their use as PDE inhibitors
HUT59403A (en) Process for producing new beta-carboline derivatives and pharmaceutical compositions comprising same
AU2026201396A1 (en) Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
US4939159A (en) Azaindole derivatives useful as cholesterol biosynthesis inhibitors
Ngochindo 2-Protecting groups for 5-lithiation in the syntheses of imidazoles
US5043327A (en) Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
JPS60149576A (ja) 坑炎症剤として有用な置換ヒドロキシ−２，３−ジヒドロベンゾフランおよびその類似体
MXPA06014131A (es) Derivado de propano-1,3-diona o su sal.
IE870217L (en) Benzothiophene derivatives
US5220023A (en) Glycine derivatives
US5120845A (en) Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives
EP0462986B1 (en) Imidazopyrimidine antiallergy agents
PL147619B1 (en) Method of obtaining novel derivatives of 6-/1-acyl-1-hydromethyl/penicillanic acid
JPWO1997000257A1 (ja) 縮合イミダゾール誘導体及びその医薬組成物
HU193633B (en) Process for production of new benzo /b/ tiofenes and tiocromates
HK1010116B (en) Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20030109

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040115

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040115

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000